SCHEMBL3017919

SCHEMBL3017919

Cc1ccc(F)cc1S(=O)(=O)N1CCN(c2nc(-c3cccc(C)c3C)cs2)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.54
ALDH1A1 P00352 4/20 0.54
LMNA P02545 4/20 0.54
MAPT P10636 3/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.51
USP2 O75604 1/20 0.51
RECQL P46063 1/20 0.51
HSD17B10 Q99714 1/20 0.51
MAPK1 P28482 4/20 0.49
AR P10275 4/20 0.45
RAB9A P51151 2/20 0.43
FABP1 P07148 1/20 0.43
FAAH O00519 2/20 0.42
HTT P42858 2/20 0.41
TSHR P16473 1/20 0.41
GBA1 P04062 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002461 0.92 ALDH1A1 (0.56) SMN1; SMN2ALDH1A1LMNAMAPTMEN1
SCHEMBL3019779 0.91 MAPT (0.53) SMN1; SMN2ALDH1A1LMNAMAPTMEN1
SCHEMBL3011733 0.91 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1LMNAMAPTMEN1
SCHEMBL3014560 0.89 ALDH1A1 (0.56) SMN1; SMN2ALDH1A1LMNAMAPTMEN1
SCHEMBL3010061 0.87 ALDH1A1 (0.54) SMN1; SMN2ALDH1A1LMNAMAPTMEN1
SCHEMBL3012413 0.87 ALDH1A1 (0.68) SMN1; SMN2ALDH1A1LMNAMAPTMEN1
SCHEMBL3008112 0.87 AR (0.54) SMN1; SMN2ALDH1A1LMNAMAPTMEN1
SCHEMBL3008974 0.86 AR (0.58) SMN1; SMN2ALDH1A1LMNAMAPTMEN1
SCHEMBL3006417 0.85 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1LMNAMAPTMEN1
SCHEMBL3004463 0.85 AR (0.43) SMN1; SMN2ALDH1A1LMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.